Bluebird Bio's Acquisition Set to Finalize on June 2, 2025
Deal News | May 30, 2025 | SK Capital
Carlyle Group and SK Capital Partners have announced the conclusion of a successful tender offer for Bluebird Bio, Inc., with all conditions met. The acquisition, which involves either a cash payment of $3.00 per share and a contingent value right (CVR) or a cash payment of $5.00 per share, is scheduled to be completed on June 2, 2025. The merger will occur without a vote from Bluebird stockholders and is in accordance with Delaware's corporate law. Bluebird Bio, a leader in the gene therapy sector, has been pioneering advancements in therapies for severe genetic diseases. Carlyle Group, with extensive assets under management, and SK Capital, focused on transformational investments in life sciences, are poised to leverage Bluebird's capabilities and data set in gene therapy. The announcement also contains forward-looking statements concerning the potential benefits of the transaction, the commercialization prospects of Bluebird's products, and associated risks.
Sectors
- Private Equity
- Biotechnology and Gene Therapy
- Pharmaceuticals and Life Sciences
Geography
- United States – The companies involved, including Bluebird Bio and the investment partners Carlyle and SK Capital, are primarily operating out of the US.
Industry
- Private Equity – The article involves Carlyle and SK Capital, both of which are prominent players in the private equity industry.
- Biotechnology and Gene Therapy – Bluebird Bio operates within the biotechnology industry, specializing in gene therapy, a focus of the merger.
- Pharmaceuticals and Life Sciences – The acquisition involves companies in sectors related to pharmaceuticals and life sciences, given Bluebird's focus on genetic diseases.
Financials
- $3.00 per share in cash with a contingent value right payment of $6.84 – This is one of the options offered to Bluebird Bio shareholders in the acquisition deal.
- $5.00 per share in cash – The alternative payment option for Bluebird Bio shareholders.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Bluebird Bio, Inc. | Target | Company | A pioneering gene therapy company focusing on severe genetic diseases. |
| Carlyle Group | Bidding Company | Company | A global investment firm that is leading the acquisition of Bluebird Bio. |
| SK Capital Partners | Bidding Company | Company | A private investment firm focused on transformative investments in life sciences. |
| Beacon Parent Holdings, L.P. | Other Company | Company | Involved in the acquisition process. |
| Beacon Merger Sub, Inc. | Other Company | Company | A subsidiary involved in the merger process with Bluebird Bio. |
| Equiniti Trust Company, LLC | Other Company | Company | The depositary advising in the tender offer process. |